cyrilzakka/clinical-trials huggingface dataset:
Patient Satiety as an Indicator of Stomach Contents and Fluid Volume

This research proposal aims to investigate the correlation between a) the hunger feeling as measured by a ten point scale and b) total gastric fluid volumes and content as measured with gastric PoCUS in fasted, healthy subjects \> 18 of age, scheduled for elective surgery.

An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale. Patient data and satiety score will be collected on a standardized form (Appendix IIb). The scanning anaesthesiologist is blinded to the result of the questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* - Age ≥ 18 years
* Fasted according to national guidelines
* Elective surgery
* ASA physical status I-II
* Ability to assume both supine and right lateral decubitus position.
* Able to understand and to sign informed consent

Exclusion Criteria:

* - Previous esophagus and gastric surgery, hiatal hernia, gastric cancer.
* Pregnancy
* Failure of GUS (defined as failure to visualize the antrum)
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL

, non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T cell lymphoma.


Eligibility Criteria:
Inclusion Criteria:

* age 18-70 years ,Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria
* at least one measurable lesion
* hemoglobin ≥90 g/l, absolute neutrophil count ≥ 1.5 × 10\^9/L, platelets ≥ 75 ×10\^9/L), ALT≤ 2 times upper limit of normal, serum creatinine ≤1.5 times upper limit of normal （If the above indicators are abnormal but are caused by the primary disease as assessed by the clinician, the treatment can be enrolled according to the clinical actual situation）
* There was no other serious disease in conflict with this program
* Adequate respiratory function
* Adequate bone marrow function
* Adequate renal and hepatic function
* Not pregnant or nursing ,negative pregnancy test
* No other active malignancy requiring therapy
* No other serious or life-threatening condition deemed unacceptable by the principal investigator
* Life expectancy ≥ 3 months
* Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

* NK/T cell lymphoma without confirmed pathological diagnosis;
* Patients with early stage upper aerodigestive tract NK/T- cell lymphoma ;
* Patients with drug allergies or metabolic disorders in the program;
* Any uncontrolled medical diseases (including uncontrolled diabetes, severe heart, lung, liver and kidney dysfunction);
* Severe infection (excluding the following: HBsAg or anti-HBc positive patients taking entecavir, tenofovir and other drugs;HCV RNA positive but taking direct anti-HCV drugs);
* Invasion of primary or secondary central nervous system tumor invasion;
* Contradictions to chemotherapy or radiotherapy;
* Previously other malignancy requiring therapy;
* Peripheral nervous system disorder or mental disorder;
* Incapacity for legal conduct, medical or ethical reasons that affect the continuation of the research;
* Other clinical investigators;
* Combination of anti-tumor drugs outside the research program;
* Participants evaluated inappropriate to participate in this study by principal investigator.
Assessment of Anti-aging Efficacy of Marine Collagen Peptides

To assess the anti-aging efficacy of Marine Collagen Peptides on skin, hair and finger nails for human


Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged above 18 years old

Exclusion Criteria:

* Subjects who are not volunteers
* Subjects who have been diagnosed with dermatitis, cirrhosis, and chronic kidney failure
* Subjects who have known cosmetic, drug or food allergies.
* Patients are taking medicine for chronic diseases
* Subjects receiving treatments for scalp, hair transplant, and other scalp medical care in past 12 weeks.
* Subjects getting a manicure and perm in past 12 weeks.
* Female who is pregnant or nursing or planning to become pregnant during the course of the study.
* Subjects receiving facial laser therapy, chemical peeling or UV overexposure (\&gt; 3 hr/week) in the past 12 weeks.
* Students who are currently taking courses taught by the principal investigator of this trial.
* Subjects are not willing to reveal the results of pictures after taking the product
* Vegetarian.
BPA Levels Relationship With IVF/ICSI Outcomes in Low Ovarian Reserve

The relationship between BPA elevation in urine, blood, and follicle fluid and embryo quality, IVF/ICSI outcomes.


Eligibility Criteria:
Inclusion Criteria:

* patients who underwent IVF due to low ovarian reserve
* patients provided urine, blood, and follicle fluid (FF) samples on the oocyte retrieval day
* patients who did not smoke or use alcohol
* patients did not work in the plastic industry

Exclusion Criteria:

* patients who underwent IVF due to unexplained infertility or tubal factor or male factor indications
* patients diagnosed with endometriosis
* patients with freeze-all cycles
* patients having previous ovarian surgery
* women with metabolic disease (such as hypertension or diabetes mellitus)
* patients with a known genetic problem (male or female)
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.


Eligibility Criteria:
Inclusion Criteria:

1. Histologically or cytologically confirmation of renal cell carcinoma with a clear cell histologic component
2. Patients must present with stage IV disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent.
3. Measurable disease according to RECIST criteria are required but patients with evaluable lesions without measurable lesions are allowed to be enrolled to this study
4. ECOG performance status 2 or better
5. Age 18 years or older
6. Adequate bone marrow, hepatic, and renal function
7. Life expectancy of \> 3 months
8. Singed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

Exclusion Criteria:

1. Known spinal cord compression or carcinomatous meningitis
2. Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri
3. Hypertension that cannot be controlled by medications (blood pressure \> 150/90 mmHg despite optimal medical therapy)
4. Treatment with anticonvulsant agents and treatment with therapeutic doses of coumadin currently or within 2 weeks prior to first day of sunitinib administration. Low dose coumadin for DVT prophylaxis is permitted (up to 2 mg/day).
5. Pregnancy or breast feeding.
6. Other severe acute or chronic medical or psychiatric condition
7. Prior treatment on sunitinib, sorafenib, or bevacizumab.
Circadian Clocks and Eating Patterns (Cohort)

For women of reproductive age, the overall postpartum weight retention (weight gain between pregnancies) plays a significant role in long-term obesity. With 20% of women retaining ≥ 5 kg at 12 months postpartum, the risk of developing conditions, such as gestational diabetes mellitus (GDM), metabolic syndrome (MS) and subsequently diabetes and cardiovascular diseases, is substantially increased. In post-GDM mothers (women who had GDM in their recent pregnancy), postpartum weight retention is also an essential predictor of future diabetes.

Recent studies have identified the impact of circadian rhythms (influencing sleep/wake cycles) and diurnal rhythm of eating (when and how often calories are consumed over a 24h period) on cardio-metabolic disorders. In women, one remarkable feature of the postpartum period is an 'externally imposed' circadian misalignment of both sleep and eating rhythms, because most babies take several weeks to months to establish their daily pattern of activity and feeding, which is particularly relevant for breastfeeding women, as the responsibility is generally on the mother.

The overarching goal of this project is to explore the interplay between the diurnal rhythm of eating, circadian and metabolic parameters in humans. The potential postpartum effects of circadian disruption will be unraveled in women who had GDM during their pregnancy and those with an uneventful pregnancy. These women are subject to a circadian misalignment due to their 'externally imposed' changes in sleep/wake cycles and eating times in the postpartum period.

With a comprehensive approach combining molecular characterization of in vivo and in vitro circadian clock parameters along with metabolic, endocrine, transcriptomic, and lipidomic studies, the investigators will assess if eating duration and/or circadian misalignment impact on circadian clock parameters of postpartum women in a prospective cohort of 6 months.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-40 years
* Breastfeeding mothers at 4-8 week postpartum
* With or without gestational diabetes mellitus diagnosed at 24-32 gestational weeks, according to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) consensus criteria
* Confident use of a smartphone and able to take regular pictures of food/drinks

Exclusion Criteria:

* Pre-existing diabetes (prior to pregnancy)
* Major illness/fever over the 2 weeks (prior to the visits with blood tests)
* Shift work or work at irregular hours planned after maternity leave
* Active cancer and/or oncologic treatment over the previous 12 months
* Coagulation disorder, on regular anticoagulant drug, skin disorder affecting wound healing
* Enrolled in a clinical trial / intervention study
* Major known mental illness, unable to give informed consent
* Inability to follow the study procedures
A Study of Modified mRNA Vaccines in Healthy Adults

The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18 to 75 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening. For mRNA-1647 study arms, adults 18 to \<50 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening.
* Body mass index (BMI) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the screening visit.

Exclusion Criteria:

* Participant has had close contact to someone with confirmed SARS-CoV-2, respiratory syncytial virus (RSV), or influenza infection in the past 14 days prior to the screening visit.
* Severe allergic reaction to any component of the FLUAD vaccine (active comparator), including egg protein, or after a previous dose of any influenza vaccine.
* Participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to screening (to include any systemic corticosteroids) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
* Participant plans to receive any licensed or authorized vaccine, including COVID-19 influenza vaccines, within 28 days before or after any study injection.
* Participant has received a NH 2021 - 2022 or 2022-2023 seasonal influenza vaccine or any other influenza vaccine, or an experimental RSV or cytomegalovirus (CMV) vaccine, within 6 months prior to study Day 1, and/or has not completed a primary vaccination series for COVID-19.
* Participant has received an authorized or approved COVID-19 vaccine within 4 months prior to Day 1, and/or has not completed a primary vaccination series for COVID-19.
* Participant had a laboratory-confirmed infection with influenza or RSV within 6 months prior to Day 1, or SARS-CoV-2 within 4 months of Day 1. SARS-CoV-2 infection confirmed with self-administered, authorized or approved rapid antigen test is acceptable.
* Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study.
* Participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study until 12 months after their last study vaccination.

Other inclusion and exclusion criteria may apply.
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers


Eligibility Criteria:
Inclusion Criteria:

* HCV RNA ≥ 100,000 IU/mL at screening
* Genotype 1a or 1b

Exclusion Criteria:

* Current or prior treatment with IFN and/or RBV
* Evidence of decompensated liver disease
Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.

In different studies, it has been shown that "antioxidant" utilization has favorable therapeutic effects not only on control of acute symptoms but also on prevention of delayed problems from acute and chronic pyelonephritis.

According to the efficacy of acetylcysteine as a potent antioxidant, safety of this drug and side effects of similar or either less than placebo, this study was designed to evaluate the efficacy of this drug on inflammatory biomarkers of pediatric acute pyelonephritis. It is a triple-blind placebo controlled study on a population of 64 patients 1-16 years old that have "definite" or "probable" diagnosis of acute pyelonephritis in "Mofid" hospital.

After randomization, patients will be given acetylcysteine or placebo with dosing according to their weight. Results of treatment are evaluated according to serum procalcitonin, C reactive protein and leukocyte count before drug prescription (baseline) and 5 days after drug prescription. Side effects are also recorded in both groups. Patients will be receiving their routine antimicrobial drugs in addition to acetylcysteine.


Eligibility Criteria:
Inclusion Criteria:

* Patients between the ages of 1 and 16
* Having the diagnosis of "definite" or "probable" urinary tract infection according to guidelines of "pediatric infectious disease research center

Exclusion Criteria:

* Patients younger than 1 or older than 16 years old
* Patients without the diagnosis of "definite" or "probable" urinary tract infection according to guidelines of "pediatric infectious disease research center"
* Patients with acute/ chronic infectious or inflammatory diseases other than pyelonephritis.
The Healthy Lifestyles Passport Program: a Nutrition Education Program to Prevent Childhood Obesity

The purpose of this study is to evaluate the effectiveness of the Healthy Lifestyles Passport Program (HLPP) in preventing infant and childhood obesity. It is hypothesized that the participants in the intervention arm will exhibit less excessive weight-for-length gain from 4- to 6-months of age. In 2-years and 5-years, it is predicted that the participants in the intervention arm will yield lower Body Mass Index (BMI) z-scores than the participants in the control arm, who receive usual care.


Eligibility Criteria:
Inclusion Criteria:

* pregnant women during the third trimester (\>28 weeks gestation) receiving care in the institution's Women's Health Center
* no medical conditions complicating their pregnancy
* must be able to communicate in English or Spanish
* be reachable by phone
* plan to be the consistent caretaker of the child at least 75% of the time
* plan to attend the institution's pediatric outpatient clinic for the child's routine healthcare

Exclusion Criteria:

* Child with any disabling or chronic illnesses
* Any existing and/or pre-existing disabling or chronic illnesses that would qualify the mother as "high risk"
* Wards of the state
* Mothers with a disabling/serious chronic illness
* Drug/alcohol use during pregnancy
Measure the Meridian Energy Change of Terminal Hospice Patient Via Meridian Energy Analysis Device

In the hospice ward, there are lots of suffered hospital patients with multiple physical discomfort related to terminal disease. Investigators want to use an objective measure instrument to monitor the effects of complementary and alternative medicine and clinical symptoms. First, investigators use the Meridian Energy Analysis Device (MEAD) to measure the bilateral 12 Yuan points (primary points) of terminal hospice patients. It provides the prediction value between terminal disease and the change of different meridian energy. Besides, the meridian energy value maybe predict the survival period. Then, the intervention of complementary and alternative medicine can also monitor via MEAD.

In the hospice ward, there are lots of suffered hospital patients with multiple physical discomfort related to terminal disease. It may be caused by cancer or multiple kinds of organ failure. The terminal hospital patients have symptoms such as pain, dyspnea, fatigue, nausea, vomiting, poor appetite, constipation, ileus or edema..., etc. Investigators want to use an objective measure instrument to monitor the effects of complementary and alternative medicine.

First, investigators use the Meridian Energy Analysis Device (MEAD) to measure the bilateral 12 Yuan points (primary points) of terminal hospice patients (divided to cancer, multiple kinds of organ failure). It provides the prediction value between terminal disease and the change of different meridian energy. Besides, the meridian energy value maybe predict the survival period. Then, investigators use the intervention of complementary and alternative medicine (like infrared lamp and acupressure..., etc.) to improve the quality of life in the terminal hospice patients. Also, investigators will use the Meridian Energy Analysis Device, pain scale, vital signs and quality of life scale (SF-36) to evaluate the effects of complementary and alternative medicine.

Eligibility Criteria:
Inclusion Criteria:

* Patients lived at our Changhua Christian Hospital hospice ward
* From 2019-02\~2020-12, age 20 to 99 years old, volunteer patient

Exclusion Criteria:

* Unwillingness
* Wound or amputation near wrist or ankle
* Severe agitation or seizure patients
Veteran Affairs Osteoarthritis Knee Study

A clinical study at the Dallas Veterans Affairs, is being proposed to test the efficacy of a novel electrical stimulation platform named the Pro-Sport Ultra® device by AVAZZIA to reduce pain and increase activity level in patients with knee osteoarthritis.

The primary objective of this study is to document the possible short- and long-term decrease in pain as scored by participants on a Numeric Rating Scale (NRS) after use of Avazzia PRO-Sport Ultra® device with pulsed microcurrent in patients with osteoarthritis of the knee.

Patients with a clinical diagnosis of Osteoarthritis (OA) of the knee for a minimum of 6 months will be recruited for this study. Their OA has not responded/is not responding to treatment and continuing symptoms interfere with normal function. Additionally, patients will have a pain score of 3 or greater on the NRS even with pain medication.

Secondary objectives include changes in:

* Mobility via a Timed Up \& Go assessment (TUG). Participants are timed getting up from sitting in a standard armchair, walking approximately 3 meters, turning, walking back to the chair, and sitting down.
* Patient-relevant outcomes via the Knee Injury and Osteoarthritis Outcome Score (KOOS). The KOOS is self-administered and assesses five outcomes: pain, symptoms, activities of daily living, sport and recreation function, and knee-related quality of life.
* Brief Pain Inventory - Short Form
* Use of pain medication.

Eligibility Criteria:
Inclusion Criteria:

* Have a prior diagnosis (Dx) of OA of the knee and have had a trial of conservative treatment for a minimum of 6 months without successful results due to continuing symptoms that interfere with normal function
* Age \>18 - \<70 years old
* Males/Females of all ethnicities
* NRS pain score of 3 or greater while on medication
* Ability to understand the informed consent document before signing it
* For female participants, is at least 4 years post-menopausal, has a history of hysterectomy, has had bilateral tubal ligation, or consents to use two forms of birth control.

Exclusion Criteria:

* Poor diabetic control (A1c\>11 within the last 3 months)
* Diagnosis of acute sciatica and/or acute vasculitis
* Diabetic peripheral neuropathy
* Lower extremity surgery within the last 6 months
* Knee replacement
* Uncontrolled mood disorders, such as depression, anxiety
* Drug or substance abuse within past 90 days
* Injury that results in a change in pain level due to causes other than osteoarthritis (i.e., a recent fall or accident)
* Epilepsy
* Open wounds around knee joint
* Active litigation, workers compensation
* An electrically implanted device such as a pacemaker, neural stimulator, etc.
* Currently pregnant, nursing, or may become pregnant.